B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Montserrat, E ^a,b   Bosch, F ^a   Rozman, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

B cell chronic lymphocytic leukemia; CLL biology; CLL diagnosis; CLL therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; FLUDARABINE PHOSPHATE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; FEMALE; GENETIC RISK; HUMAN; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030927114     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S93     Document Type: Conference Paper

References (119)

1. Galton DAG. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94: 1005-10.
2. Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566-84.
3. Finch SC, Linet MS. Chronic lymphocytic leukaemias. Baillère's Clin Haematol 1992; 5: 27-56.
4. Rozman C (ed). Chronic lymphocytic leukaemia and related disorders. Baillière's Clinical Haematol 1993; 6: 757-919.
5. Gale RP, Caligaris-Cappio F, Dighiero G et al. (International Workshop on CLL). Recent progress in chronic lymphocytic leukemia. Leukemia 1994; 8: 1610-4.
6. Cheson BD. Chronic lymphocytic leukemia and hairy-cell leukemia. Current Opinion Haematol 1994; 1: 268-77 & B91-3.
7. Montserrat E, Rozman C. Chronic lymphocytic leukemia: Present status. Ann Oncol 1995; 6: 219-35.
8. O'Brien S, del Giglio A, Keating MJ. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307-18.
9. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-7.
10. Caligaris-Cappio F. B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 1996; 87: 2615-20.
11. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic immune disorders. Blood 1993; 10: 2475-87.
12. Centola M, Lin K, Sutton C et al. Production of anti-erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Leuk Lymph 1996; 20: 465-9.
13. Han T, Henderson ES, Emrich LJ, Sandberg AA. Prognostic significance of karyotypic abnormalities in B cell chronic lymphocytic leukemia: An update. Sem Hematol 1987; 24: 257-65.
14. Juliusson G, Gahrton G. Cytogenetics in CLL and related disorders. Baillière's Clin Haematol 1993; 6: 821-48.
15. Escudier SM, Pereira-Leahy JM, Drach JW et al. Fluorescence in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993; 81: 2702-7.
16. Que TH, Marco JG, Ellis J et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: Analysis by stage, immunophenotype, and morphology. Blood 1993; 82: 571-5.
17. Criel A, Wlodarska I, Meeus P et al. Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias. Br J Haematol 1994; 87: 523-8.
18. Offit K, Louie DC, Parsa NZ et al. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 1994; 83: 2611-8.
19. Jabbar SAB, Ganeshaguru K, Wickremasinghe RG et al. Deletion of chromosome 13 (band q14) but not trisomy 12 is a clonal event in B-chronic lymphocytic leukaemia (CLL). Br J Haematol 1995; 90: 476-8.
20. Peterson LC, Parsons R, Church S et al. Karyotypic evolution correlates with disease progression in B-cell chronic lymphocytic leukemia (B-CLL). Proc Am Soc Clin Oncol 1993; 12: 313 (Abstr).
21. Fegan C, Robinson H, Thompson P et al. Karyotypic evolution in CLL: Identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9: 2003-8.
22. Rechavi G, Katzir N, Brok-Simoni F et al. A search for bell, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. Leukemia 1989; 3: 57-60.
23. Gaidano G, Newcomb EW, Gong JZ et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol 1994; 144: 1312-9.
24. Ohno H, Doi S, Yabumoto K et al. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia 1993; 7: 2057-63.
25. Shustick C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia. Br J Haematol 1991; 79: 50-6.
26. Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB. Common expression of the multidrug resistance marker p-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 1993; 17: 941-7.
27. Wulf G, Kluding H, Ho AD et al. Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern blot analysis. Leuk Res 1994; 18: 457-84.
28. Sonneveld P, Nooter K, Burghouts JThM et al. High expression of the mdr-3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496-1500.
29. Hanada M, de Delia A, Aiello E et al. Bcl-2 gene hypomethylation and high levels of expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820.
30. Thomas A, El Rouby S, Reed S et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutations and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-62.
31. McConkey DJ, Chandra J, Wright S et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156: 2624-30.
32. Watanabe T, Ichikawa A, Alto H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymph 1996; 21: 391-7.
33. Newcomb EW, Rao LS, Giknavorian SS, Lee SY. Alterations of multiple suppressor genes (p53 [17p13], p16INKA [9p21], and DBM [13q14]) in B-cell chronic lymphocytic leukemia. Mol Carcinog 1995; 14: 141-6.
34. Newcomb EW, Thomas A, Selkirk A et al. Frequent homozygous deletions of D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res 1995; 55: 2044-7.
35. Delmer A, Ajchebaum-Cymbalista F, Tang R et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995; 85: 2870-6.
36. + B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. Blood 1996; 87: 1900-11.
37. Gartenhaus R, Johns MM III, Wang P et al. Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood 1996; 87: 38-41.
38. Kay NE, Ranheim EA, Peterson LC. Tumor suppressor genes and clonal evolution in B-CLL. Leuk Lymph 1995; 18: 41-9.
39. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995; 85: 1913-9.
40. Van Kooten C, Rensink I, Aarden L, van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells. Blood 1992; 80: 1299-1306.
41. Mainou-Fowler T, Craig VA, Copplestone A et al. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression, and is inhibited by IL-4. Blood 1994; 84: 2297-2304.
42. Trentin L, Zambello R, Agostini C et al. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 4249-56.
43. Mainou-Fowler T, Prentice AG. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Leuk Lymph 1996; 369-78.
44. Chaouchi N, Wallon C, Goujard C et al. Interleukin-13 inhibits interleukin-2 induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996; 87: 1022-9.
45. Trentin L, Ceruti A, Zambello R et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996; 87: 3327-35.
46. Cheson BD, Bennet JM, Rai KR et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 1988; 29: 152-63.
47. International Workshop on CLL. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110: 236-8.
48. Matutes E, Owusu-Ankomah K, Morilla R et al. The immunologic profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-5.
49. Bennet JM, Catovsky D, Daniel MT et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 1989; 42: 567-84.
50. Litz GE, Brunning RD. Chronic lymphoproliferative disorders: Classification and diagnosis. Baillière's Clin Haematol 1993; 6: 767-83.
51. Mulligan S, Catovsky D. Splenic lymphoma with villous lymphocytes. Leuk Lymph 1991; 6: 97-105.
52. Pangalis GA, Boussiotis VA, Kittas C. Malignant disorders of small lymphocytes. Am J Clin Pathol 1993; 99: 402-8.
53. Raffeld M, Sander CA, Yano T, Jaffe ES. Mantle cell lymphoma: An update. Leuk Lymph 1992; 8: 161-6.
54. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.
55. Binet JL, Auqier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
56. International Workshop on CLL. Chronic lymphocytic leukaemia: Proposals for a revised prognostic staging system. Br J Haematol 1981; 48: 365-7.
57. Rozman C, Montserrat E, Rodriguez-Fernández JM et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 1984; 64: 642-8.
58. Geisler C, Ralfkiaer E, Hansen MM et al. The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukemia. Br J Haematol 1986; 62: 47-54.
59. Montserrat E, Villamor N, Reverter JC et al. Bone marrow assessment in chronic lymphocytic leukemia: Bone marrow aspirate or biopsy? A study based on 327 patients. Br J Haematol 1996 (in press).
60. Rozman C, Montserrat E, Feliu E et al. Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood 1982; 59: 1001-5.
61. Montserrat E, Sánchez-Bisonó J, Viñolas N et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 1986; 62: 567-75.
62. Vallespi T, Montserrat E, Sanz MA. Chronic lymphocytic leukaemia: Prognostic value of lymphocyte morphological subtypes. A multivariate analysis in 146 patients. Br J Haematol 1991; 77: 478-85.
63. Montserrat E, Viñolas N, Reverter JC et al. Natural history of chronic lymphocytic leukemia: On the progression and prognosis of early clinical stages. Nouv Rev Fr Hèmatol 1988; 30: 359-61.
64. Ellims PH, Gan TE, van der Weyden MB. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br J Haematol 1981; 49: 479-85.
65. Lee JS, Dixon DO, Kantarjian HM et al. Prognosis of chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929-36.
66. Reinisch W, Willheim M, Hilgarth M et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12: 2146-52.
67. Keating MJ, Lerner S, Kantarjian H et al. The serum B2-microglobulin (B2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1995; 86: 606a (Abstr).
68. Montserrat E, Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev 1993; 7: 164-75.
69. Shustik C, Mick R, Silver R et al. Treament of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol Oncol 1988; 6: 7-12.
70. French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of a randomized clinical trial on 612 patients. Blood 1990; 75: 1414-21.
71. Catovsky D, Richards S, Fooks J et al. (MRC Working Party on Leukaemia in Adults). CLL trials in the United Kingdom. Leuk Lymph 1991; 5 (Suppl): 105-12.
72. Spanish Cooperative Group PETHEMA. Treatment of chronic lymphocytic leukemia: Preliminary report of Spanish (PETHEMA) trials. Leuk Lymph 1991; 5: 89-91.
73. Brugiatelli M, Jaksic B, Planic-Peraica A et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: Long-term results of a randomized trial. Eur J Haematol 1995; 55: 158-63.
74. Jaksic B, Brugiatelli M. High-dose continuous chlorambucil vs. intermittent chlorambucil plus prednisone for treatment of B-CLL, IGCI CLL-01 trial. N Rev Fr Hématol 1988; 30: 437-42.
75. Jaksic B, Brugiatelli M, Krc I et al. Comparison of high-dose chlorambucil versus Binet's modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: Results of an international multicentric randomized trial. Blood 1995; 86: 607a (Abstr).
76. Montserrat E, Alcalá A, Parody R et al. Treatment of chronic lymphocytic leukemia in advanced stage: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369-75.
77. Raphael B, Andersen JW, Silber R et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991; 9: 770-6.
78. Montserrat E, Alcalá A, Alonso C et al. A randomized trial comparing chlorambucil plus prednisone vs. cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. N Rev Fr Hematol 1988; 30: 429-32.
79. Hansen MM, Andersen E, Birgens H et al. CHOP versus chlorambucil plus prednisolone in chronic lymphocytic leukemia. Leuk Lymph 1991; 5 (Suppl): 97-100.
80. Kimby E, Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type: A randomized trial. Leuk Lymph 1991; 5 (Suppl): 93-6.
81. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1670-95.
82. Keating MJ, O'Brien S, Kantarjian H et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84.
83. Tallman MS, Hakimian D. Purine nucleoside analogs: Emerging roles indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74.
84. Aabo K, Walbom-Jorgensen S. Spleen irradiation in chronic lymphocytic leukemia (CLL): Palliation in patients unfit for splenectomy. Am J Hematol 1985; 19: 177-80.
85. Chikappa G, Pasquale D, Zarrabi MH et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol 1992; 41: 5-12.
86. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized controlled clinical trial. N Engl J Med 1988; 319: 902-7.
87. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6.
88. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haem 1995; 17: 75-80.
89. Chapel H, Dicato M, Gamm H et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of two dose regimes. Br J Haematol 1994; 88: 209-12.
90. Jurlander J, Hartmann Geisler C, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994; 53: 114-8.
91. Hollander AAMJ, Kluin-Nelemans HC, Haak HR et al. Correction of neutropenia associated with chronic lymphocytic leukemia following treatment with granulocyte-macrophage colony-stimulating factor. Ann Hematol 1991; 62: 32-4.
92. Pangalis GA, Poziopoulos Ch, Angelopoulo MK et al. Effective treatment of anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995; 89: 627-9.
93. Robertson LE, Pugh W, O'Brien S et al. Richters syndrome: A report of 39 patients. J Clin Oncol 1993; 11: 1985-9.
94. Rai KR, Peterson B, Kolitz J et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL): A randomized intergroup study. Blood 1995; 86 (Suppl 1): 607a(Abstr).
95. French Cooperative Group on CLL. Comparison of fludarabine (FDB), CAP, and CHOP in previously untreated stage B and C chronic lymphocytic leukemia (CLL): First interim results of a randomized clinical trial in 247 patients. Blood 1994; 84 (Suppl 1): 461a (Abstr).
96. The French Cooperative Group on CLL et al. Multicentre prospective randomised trial of fludarabine versus cyclophiosphamide, doxorubicin, and prednisone (CAP) for treatment of advancedstage chronic lymphocytic leukaemia. Lancet 1996 (in press).
97. Saven A, Lemon RH, Kosty M et al. 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-4.
98. Delannoy A, Martial P, Gala JL et al. 2-chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5.
99. Cheson BD. Infectious and immunosuppresive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48.
100. Di Raimondo F, Giustolisi R, Cacciola E et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymph 1993; 11: 63-8.
101. Myint H, Copplestone A, Orchad J et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-4.
102. Frame JN, Dahut WL, Crowley S. Fludarabine and acute tumor lysis syndrome in chronic lymphocytic leukemia. N Engl J Med 1992; 5: 1396 (Letter).
103. Maung ZT, Wood AC, Jackson GH et al. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1994; 88: 649-52.
104. Briz M, Cabrera R, Sanjuán I et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 409-11.
105. Slickney DR, Foon KA. Biologic response modifiers: Therapeutic approaches to lymphoproliferative diseases. Curr Opin Oncol 1992; 4: 847-55.
106. Grossbard ML, Press OW, Appelbaum FR et al. Monoclonal antibody-based therapies for leukemia and lymphoma. Blood 1992; 80: 863-78.
107. Rabinowe SN, Grossbard ML, Nadler LM. Innovative treatment strategies for chronic lymphocytic leukemia: Monoclonal antibodies, immunoconjugates, and bone marrow transplantation. In Cheson BD (ed): Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York: Marcel Dekker, Inc. 1993; 337-67.
108. Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755-8.
109. Montserrat E, Villamor N, Urbano-Ispizua A et al. Alpha interferon in chronic lymphocytic leukaemia. Eur J Cancer 1991; 27 (Suppl 4): 74-7.
110. O'Brien S, Kantarjian H, Beran M et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 1995; 86: 1296-1300.
111. Zinzani PL, Levrero MG, Lauria F et al. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Haematologica 1994; 79: 55-60.
112. LeMaistre CF, Meneghetti C, Rosenblum M et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547-54.
113. 486IL-2) in a patient with chronic lymphocytic leukaemia. Lancet 1991; 337: 1124-25.
114. +B (B-1) cells by antisense IL-10 oligonucleotide. Leuk Res 1995; 19: 159-67.
115. Michallet M, Archimbaud E, Rowlings PA et al. Hematopoietic stem cell transplant for chronic lymphocytic leukemia. Bone Marrow Transpl 1996; 17 (Suppl 1): S3 (Abstr).
116. Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-76.
117. Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 1994; 12: 748-58.
118. Mehta J, Powels R, Singhal S et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: Possible role of graft versus leukemia. Bone Marrow Transplant 1996; 17: 371-5.
119. Sadoun A, Patri S, Delwail V et al. Molecular remission after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1994; 13: 217-9.